Cue Biopharma (CUE) Current Deferred Revenue (2017 - 2018)
Cue Biopharma's (CUE) quarterly Current Deferred Revenue came in at $381465.0 in Q4 2018, up 949.02% year-on-year from $36364.0 in Q4 2017, and up 69.54% quarter-over-quarter from $225000.0 in Q3 2018.
Cue Biopharma (CUE) Current Deferred Revenue (2017 - 2018) Analysis & Trends
Cue Biopharma has disclosed Current Deferred Revenue across 2 years of filings, most recently posting $381465.0 for Q4 2018.
- Current Deferred Revenue for Q4 2018 came in at $381465.0, up 949.02% year-over-year; the trailing twelve-month figure through Dec 2018 was $381465.0 (up 949.02% YoY), and the FY2018 annual result was $381465.0, up 949.02% from the prior year.
- Current Deferred Revenue came in at $381465.0 for Q4 2018 at Cue Biopharma, up from $225000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $381465.0 in Q4 2018 to a low of $36364.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Cue Biopharma | 581.16 Mn | 553.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 381,465.00 |
| Sep 30, 2018 | 225,000.00 |
| Jun 30, 2018 | 75,000.00 |
| Dec 31, 2017 | 36,364.00 |